nodes	percent_of_prediction	percent_of_DWPC	metapath
Capecitabine—breast cancer—bone cancer	0.27	0.385	CtDrD
Capecitabine—prostate cancer—bone cancer	0.25	0.357	CtDrD
Capecitabine—kidney cancer—bone cancer	0.182	0.259	CtDrD
Capecitabine—TYMS—Methotrexate—bone cancer	0.108	0.891	CbGbCtD
Capecitabine—CYP2C9—Cisplatin—bone cancer	0.0131	0.109	CbGbCtD
Capecitabine—DPYD—Pyrimidine catabolism—NT5C3A—bone cancer	0.0105	0.144	CbGpPWpGaD
Capecitabine—TYMP—Pyrimidine catabolism—NT5C3A—bone cancer	0.00752	0.103	CbGpPWpGaD
Capecitabine—DPYD—Pyrimidine metabolism—NT5C3A—bone cancer	0.00606	0.0828	CbGpPWpGaD
Capecitabine—CDA—Pyrimidine metabolism—NT5C3A—bone cancer	0.0054	0.0738	CbGpPWpGaD
Capecitabine—TYMP—Pyrimidine metabolism—NT5C3A—bone cancer	0.00432	0.059	CbGpPWpGaD
Capecitabine—DPYD—Nucleotide metabolism—NT5C3A—bone cancer	0.00236	0.0323	CbGpPWpGaD
Capecitabine—TYMS—Pyrimidine metabolism—NT5C3A—bone cancer	0.00221	0.0302	CbGpPWpGaD
Capecitabine—CDA—Nucleotide metabolism—NT5C3A—bone cancer	0.0021	0.0288	CbGpPWpGaD
Capecitabine—DPYD—Fluoropyrimidine Activity—DHFR—bone cancer	0.00191	0.0261	CbGpPWpGaD
Capecitabine—CDA—Fluoropyrimidine Activity—DHFR—bone cancer	0.0017	0.0233	CbGpPWpGaD
Capecitabine—CES1—Irinotecan Pathway—CYP3A4—bone cancer	0.00169	0.0231	CbGpPWpGaD
Capecitabine—TYMP—Nucleotide metabolism—NT5C3A—bone cancer	0.00168	0.023	CbGpPWpGaD
Capecitabine—TYMP—Fluoropyrimidine Activity—DHFR—bone cancer	0.00136	0.0186	CbGpPWpGaD
Capecitabine—TYMS—G1/S-Specific Transcription—DHFR—bone cancer	0.00118	0.0162	CbGpPWpGaD
Capecitabine—CES1—Fluoropyrimidine Activity—DHFR—bone cancer	0.001	0.0137	CbGpPWpGaD
Capecitabine—TYMS—Nucleotide metabolism—NT5C3A—bone cancer	0.00086	0.0118	CbGpPWpGaD
Capecitabine—TYMS—One Carbon Metabolism—DHFR—bone cancer	0.000793	0.0108	CbGpPWpGaD
Capecitabine—TYMP—Bladder Cancer—CDK4—bone cancer	0.000751	0.0103	CbGpPWpGaD
Capecitabine—TYMS—Trans-sulfuration and one carbon metabolism—DHFR—bone cancer	0.000713	0.00975	CbGpPWpGaD
Capecitabine—TYMS—E2F mediated regulation of DNA replication—DHFR—bone cancer	0.000696	0.00951	CbGpPWpGaD
Capecitabine—TYMS—Fluoropyrimidine Activity—DHFR—bone cancer	0.000696	0.00951	CbGpPWpGaD
Capecitabine—TYMP—Bladder Cancer—BRAF—bone cancer	0.000664	0.00908	CbGpPWpGaD
Capecitabine—TYMP—Bladder Cancer—RB1—bone cancer	0.000653	0.00893	CbGpPWpGaD
Capecitabine—TYMP—Bladder Cancer—MDM2—bone cancer	0.000557	0.00761	CbGpPWpGaD
Capecitabine—CES1—E2F transcription factor network—DHFR—bone cancer	0.000531	0.00726	CbGpPWpGaD
Capecitabine—CYP2C9—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000526	0.00718	CbGpPWpGaD
Capecitabine—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—bone cancer	0.000502	0.00687	CbGpPWpGaD
Capecitabine—TYMS—Circadian rythm related genes—TNFRSF11A—bone cancer	0.000453	0.00619	CbGpPWpGaD
Capecitabine—DPYD—Fluoropyrimidine Activity—TP53—bone cancer	0.000426	0.00583	CbGpPWpGaD
Capecitabine—TYMP—Bladder Cancer—EGFR—bone cancer	0.00038	0.0052	CbGpPWpGaD
Capecitabine—CDA—Fluoropyrimidine Activity—TP53—bone cancer	0.00038	0.0052	CbGpPWpGaD
Capecitabine—TYMS—E2F transcription factor network—DHFR—bone cancer	0.000369	0.00504	CbGpPWpGaD
Capecitabine—TYMS—Retinoblastoma (RB) in Cancer—DHFR—bone cancer	0.00032	0.00438	CbGpPWpGaD
Capecitabine—TYMP—Bladder Cancer—TP53—bone cancer	0.000319	0.00437	CbGpPWpGaD
Capecitabine—TYMS—E2F mediated regulation of DNA replication—RB1—bone cancer	0.000318	0.00434	CbGpPWpGaD
Capecitabine—TYMP—Fluoropyrimidine Activity—TP53—bone cancer	0.000304	0.00415	CbGpPWpGaD
Capecitabine—CES1—E2F transcription factor network—PLAU—bone cancer	0.000295	0.00404	CbGpPWpGaD
Capecitabine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000284	0.00388	CbGpPWpGaD
Capecitabine—TYMS—G1/S Transition—DHFR—bone cancer	0.000267	0.00366	CbGpPWpGaD
Capecitabine—DPYD—Metabolism—NDUFA12—bone cancer	0.000259	0.00354	CbGpPWpGaD
Capecitabine—CYP2C9—Xenobiotics—CYP3A4—bone cancer	0.000254	0.00347	CbGpPWpGaD
Capecitabine—CYP2C9—Tamoxifen metabolism—CYP3A4—bone cancer	0.000244	0.00333	CbGpPWpGaD
Capecitabine—CES1—E2F transcription factor network—RB1—bone cancer	0.000243	0.00332	CbGpPWpGaD
Capecitabine—CDA—Metabolism—NDUFA12—bone cancer	0.000231	0.00315	CbGpPWpGaD
Capecitabine—CYP2C9—Metapathway biotransformation—CYP4V2—bone cancer	0.000226	0.00309	CbGpPWpGaD
Capecitabine—TYMS—Mitotic G1-G1/S phases—DHFR—bone cancer	0.000225	0.00308	CbGpPWpGaD
Capecitabine—CES1—Fluoropyrimidine Activity—TP53—bone cancer	0.000224	0.00306	CbGpPWpGaD
Capecitabine—CES1—NRF2 pathway—GSTP1—bone cancer	0.000221	0.00302	CbGpPWpGaD
Capecitabine—CES1—NRF2 pathway—TGFBR2—bone cancer	0.000221	0.00302	CbGpPWpGaD
Capecitabine—DPYD—Metabolism—NT5C3A—bone cancer	0.000214	0.00293	CbGpPWpGaD
Capecitabine—TYMS—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	0.000205	0.0028	CbGpPWpGaD
Capecitabine—TYMS—E2F transcription factor network—PLAU—bone cancer	0.000205	0.0028	CbGpPWpGaD
Capecitabine—TYMS—Cell Cycle, Mitotic—ZW10—bone cancer	0.000194	0.00265	CbGpPWpGaD
Capecitabine—CDA—Metabolism—NT5C3A—bone cancer	0.000191	0.00261	CbGpPWpGaD
Capecitabine—TYMP—Metabolism—NDUFA12—bone cancer	0.000184	0.00252	CbGpPWpGaD
Capecitabine—TYMS—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	0.000174	0.00238	CbGpPWpGaD
Capecitabine—CYP2C9—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000174	0.00238	CbGpPWpGaD
Capecitabine—TYMS—Cell Cycle—ZW10—bone cancer	0.000174	0.00237	CbGpPWpGaD
Capecitabine—TYMS—E2F transcription factor network—RB1—bone cancer	0.000168	0.0023	CbGpPWpGaD
Capecitabine—TYMS—Retinoblastoma (RB) in Cancer—CDK4—bone cancer	0.000168	0.0023	CbGpPWpGaD
Capecitabine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000166	0.00227	CbGpPWpGaD
Capecitabine—TYMS—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	0.000159	0.00217	CbGpPWpGaD
Capecitabine—TYMS—Fluoropyrimidine Activity—TP53—bone cancer	0.000155	0.00212	CbGpPWpGaD
Capecitabine—TYMS—Circadian rythm related genes—GNA11—bone cancer	0.000153	0.00209	CbGpPWpGaD
Capecitabine—TYMP—Metabolism—NT5C3A—bone cancer	0.000153	0.00209	CbGpPWpGaD
Capecitabine—TYMS—Circadian rythm related genes—EZH2—bone cancer	0.000153	0.00208	CbGpPWpGaD
Capecitabine—TYMS—Cell Cycle, Mitotic—TUBB4B—bone cancer	0.000147	0.00201	CbGpPWpGaD
Capecitabine—TYMS—Retinoblastoma (RB) in Cancer—RB1—bone cancer	0.000146	0.002	CbGpPWpGaD
Capecitabine—TYMS—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	0.000145	0.00198	CbGpPWpGaD
Capecitabine—TYMS—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	0.000143	0.00195	CbGpPWpGaD
Capecitabine—TYMS—Cell Cycle, Mitotic—RFC1—bone cancer	0.000133	0.00182	CbGpPWpGaD
Capecitabine—TYMS—Cell Cycle—TUBB4B—bone cancer	0.000131	0.0018	CbGpPWpGaD
Capecitabine—TYMS—Retinoblastoma (RB) in Cancer—MDM2—bone cancer	0.000125	0.00171	CbGpPWpGaD
Capecitabine—TYMS—G1/S Transition—RB1—bone cancer	0.000122	0.00167	CbGpPWpGaD
Capecitabine—TYMS—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	0.000121	0.00165	CbGpPWpGaD
Capecitabine—TYMS—Cell Cycle—RFC1—bone cancer	0.000119	0.00163	CbGpPWpGaD
Capecitabine—TYMS—Mitotic G1-G1/S phases—CDK4—bone cancer	0.000118	0.00162	CbGpPWpGaD
Capecitabine—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000105	0.00144	CbGpPWpGaD
Capecitabine—CYP2C9—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000104	0.00142	CbGpPWpGaD
Capecitabine—TYMS—Mitotic G1-G1/S phases—RB1—bone cancer	0.000103	0.00141	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—NDUFA12—bone cancer	9.43e-05	0.00129	CbGpPWpGaD
Capecitabine—DPYD—Metabolism—ENO2—bone cancer	9.39e-05	0.00128	CbGpPWpGaD
Capecitabine—TYMS—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	8.97e-05	0.00123	CbGpPWpGaD
Capecitabine—DPYD—Metabolism—DHFR—bone cancer	8.71e-05	0.00119	CbGpPWpGaD
Capecitabine—TYMS—Circadian rythm related genes—CDK4—bone cancer	8.61e-05	0.00118	CbGpPWpGaD
Capecitabine—CYP2C9—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	8.54e-05	0.00117	CbGpPWpGaD
Capecitabine—CDA—Metabolism—ENO2—bone cancer	8.37e-05	0.00114	CbGpPWpGaD
Capecitabine—TYMS—Cell Cycle, Mitotic—DHFR—bone cancer	8.27e-05	0.00113	CbGpPWpGaD
Capecitabine—DPYD—Metabolism—GNA11—bone cancer	8.14e-05	0.00111	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—NT5C3A—bone cancer	7.81e-05	0.00107	CbGpPWpGaD
Capecitabine—CDA—Metabolism—DHFR—bone cancer	7.76e-05	0.00106	CbGpPWpGaD
Capecitabine—TYMS—Cell Cycle—DHFR—bone cancer	7.39e-05	0.00101	CbGpPWpGaD
Capecitabine—DPYD—Metabolism—CYP3A4—bone cancer	7.38e-05	0.00101	CbGpPWpGaD
Capecitabine—CDA—Metabolism—GNA11—bone cancer	7.26e-05	0.000992	CbGpPWpGaD
Capecitabine—TYMS—Retinoblastoma (RB) in Cancer—TP53—bone cancer	7.16e-05	0.000978	CbGpPWpGaD
Capecitabine—TYMP—Metabolism—ENO2—bone cancer	6.69e-05	0.000915	CbGpPWpGaD
Capecitabine—TYMS—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	6.65e-05	0.000909	CbGpPWpGaD
Capecitabine—CDA—Metabolism—CYP3A4—bone cancer	6.58e-05	0.000899	CbGpPWpGaD
Capecitabine—TYMS—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	6.41e-05	0.000876	CbGpPWpGaD
Capecitabine—DPYD—Metabolism—GSTP1—bone cancer	6.31e-05	0.000863	CbGpPWpGaD
Capecitabine—TYMP—Metabolism—DHFR—bone cancer	6.21e-05	0.000848	CbGpPWpGaD
Capecitabine—TYMS—Cell Cycle—CHEK2—bone cancer	6.18e-05	0.000844	CbGpPWpGaD
Capecitabine—Hyperglycaemia—Doxorubicin—bone cancer	6.07e-05	0.000582	CcSEcCtD
Capecitabine—Agranulocytosis—Epirubicin—bone cancer	6.05e-05	0.000581	CcSEcCtD
Capecitabine—Pneumonia—Doxorubicin—bone cancer	6.03e-05	0.000579	CcSEcCtD
Capecitabine—Infestation NOS—Doxorubicin—bone cancer	6e-05	0.000576	CcSEcCtD
Capecitabine—Infestation—Doxorubicin—bone cancer	6e-05	0.000576	CcSEcCtD
Capecitabine—Visual impairment—Methotrexate—bone cancer	5.99e-05	0.000575	CcSEcCtD
Capecitabine—Stevens-Johnson syndrome—Doxorubicin—bone cancer	5.95e-05	0.000571	CcSEcCtD
Capecitabine—Hypersensitivity—Cisplatin—bone cancer	5.93e-05	0.000569	CcSEcCtD
Capecitabine—Bradycardia—Epirubicin—bone cancer	5.93e-05	0.000569	CcSEcCtD
Capecitabine—Renal failure—Doxorubicin—bone cancer	5.9e-05	0.000566	CcSEcCtD
Capecitabine—Erythema multiforme—Methotrexate—bone cancer	5.88e-05	0.000564	CcSEcCtD
Capecitabine—Neuropathy peripheral—Doxorubicin—bone cancer	5.88e-05	0.000564	CcSEcCtD
Capecitabine—Haemoglobin—Epirubicin—bone cancer	5.85e-05	0.000561	CcSEcCtD
Capecitabine—Jaundice—Doxorubicin—bone cancer	5.85e-05	0.000561	CcSEcCtD
Capecitabine—Stomatitis—Doxorubicin—bone cancer	5.85e-05	0.000561	CcSEcCtD
Capecitabine—Rhinitis—Epirubicin—bone cancer	5.84e-05	0.00056	CcSEcCtD
Capecitabine—Conjunctivitis—Doxorubicin—bone cancer	5.83e-05	0.00056	CcSEcCtD
Capecitabine—Urinary tract infection—Doxorubicin—bone cancer	5.83e-05	0.00056	CcSEcCtD
Capecitabine—Hepatitis—Epirubicin—bone cancer	5.82e-05	0.000558	CcSEcCtD
Capecitabine—Haemorrhage—Epirubicin—bone cancer	5.82e-05	0.000558	CcSEcCtD
Capecitabine—Eye disorder—Methotrexate—bone cancer	5.81e-05	0.000558	CcSEcCtD
Capecitabine—TYMP—Metabolism—GNA11—bone cancer	5.8e-05	0.000793	CbGpPWpGaD
Capecitabine—Tinnitus—Methotrexate—bone cancer	5.8e-05	0.000556	CcSEcCtD
Capecitabine—Hypoaesthesia—Epirubicin—bone cancer	5.79e-05	0.000556	CcSEcCtD
Capecitabine—TYMS—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	5.78e-05	0.00079	CbGpPWpGaD
Capecitabine—Asthenia—Cisplatin—bone cancer	5.78e-05	0.000554	CcSEcCtD
Capecitabine—Pharyngitis—Epirubicin—bone cancer	5.78e-05	0.000554	CcSEcCtD
Capecitabine—Cardiac disorder—Methotrexate—bone cancer	5.77e-05	0.000554	CcSEcCtD
Capecitabine—Urinary tract disorder—Epirubicin—bone cancer	5.75e-05	0.000552	CcSEcCtD
Capecitabine—Oedema peripheral—Epirubicin—bone cancer	5.73e-05	0.00055	CcSEcCtD
Capecitabine—Haematuria—Doxorubicin—bone cancer	5.72e-05	0.000549	CcSEcCtD
Capecitabine—Connective tissue disorder—Epirubicin—bone cancer	5.72e-05	0.000549	CcSEcCtD
Capecitabine—Urethral disorder—Epirubicin—bone cancer	5.71e-05	0.000547	CcSEcCtD
Capecitabine—Hepatobiliary disease—Doxorubicin—bone cancer	5.67e-05	0.000544	CcSEcCtD
Capecitabine—Epistaxis—Doxorubicin—bone cancer	5.66e-05	0.000543	CcSEcCtD
Capecitabine—Angiopathy—Methotrexate—bone cancer	5.64e-05	0.000541	CcSEcCtD
Capecitabine—CDA—Metabolism—GSTP1—bone cancer	5.63e-05	0.000769	CbGpPWpGaD
Capecitabine—Immune system disorder—Methotrexate—bone cancer	5.62e-05	0.000539	CcSEcCtD
Capecitabine—Visual impairment—Epirubicin—bone cancer	5.61e-05	0.000538	CcSEcCtD
Capecitabine—Mediastinal disorder—Methotrexate—bone cancer	5.61e-05	0.000538	CcSEcCtD
Capecitabine—Agranulocytosis—Doxorubicin—bone cancer	5.6e-05	0.000537	CcSEcCtD
Capecitabine—Chills—Methotrexate—bone cancer	5.58e-05	0.000535	CcSEcCtD
Capecitabine—TYMS—Circadian rythm related genes—JUN—bone cancer	5.55e-05	0.000758	CbGpPWpGaD
Capecitabine—Diarrhoea—Cisplatin—bone cancer	5.51e-05	0.000529	CcSEcCtD
Capecitabine—Erythema multiforme—Epirubicin—bone cancer	5.5e-05	0.000528	CcSEcCtD
Capecitabine—Alopecia—Methotrexate—bone cancer	5.5e-05	0.000527	CcSEcCtD
Capecitabine—Bradycardia—Doxorubicin—bone cancer	5.48e-05	0.000526	CcSEcCtD
Capecitabine—Mental disorder—Methotrexate—bone cancer	5.45e-05	0.000523	CcSEcCtD
Capecitabine—Eye disorder—Epirubicin—bone cancer	5.44e-05	0.000522	CcSEcCtD
Capecitabine—Tinnitus—Epirubicin—bone cancer	5.43e-05	0.000521	CcSEcCtD
Capecitabine—Erythema—Methotrexate—bone cancer	5.41e-05	0.000519	CcSEcCtD
Capecitabine—Malnutrition—Methotrexate—bone cancer	5.41e-05	0.000519	CcSEcCtD
Capecitabine—Haemoglobin—Doxorubicin—bone cancer	5.41e-05	0.000519	CcSEcCtD
Capecitabine—Cardiac disorder—Epirubicin—bone cancer	5.4e-05	0.000518	CcSEcCtD
Capecitabine—Flushing—Epirubicin—bone cancer	5.4e-05	0.000518	CcSEcCtD
Capecitabine—Rhinitis—Doxorubicin—bone cancer	5.4e-05	0.000518	CcSEcCtD
Capecitabine—CYP2C9—Arachidonic acid metabolism—PTGS2—bone cancer	5.4e-05	0.000738	CbGpPWpGaD
Capecitabine—Hepatitis—Doxorubicin—bone cancer	5.39e-05	0.000517	CcSEcCtD
Capecitabine—Haemorrhage—Doxorubicin—bone cancer	5.39e-05	0.000517	CcSEcCtD
Capecitabine—Hypoaesthesia—Doxorubicin—bone cancer	5.36e-05	0.000514	CcSEcCtD
Capecitabine—Pharyngitis—Doxorubicin—bone cancer	5.35e-05	0.000513	CcSEcCtD
Capecitabine—Urinary tract disorder—Doxorubicin—bone cancer	5.32e-05	0.00051	CcSEcCtD
Capecitabine—Oedema peripheral—Doxorubicin—bone cancer	5.31e-05	0.000509	CcSEcCtD
Capecitabine—Dysgeusia—Methotrexate—bone cancer	5.3e-05	0.000509	CcSEcCtD
Capecitabine—Connective tissue disorder—Doxorubicin—bone cancer	5.29e-05	0.000508	CcSEcCtD
Capecitabine—Angiopathy—Epirubicin—bone cancer	5.28e-05	0.000507	CcSEcCtD
Capecitabine—Urethral disorder—Doxorubicin—bone cancer	5.28e-05	0.000507	CcSEcCtD
Capecitabine—TYMP—Metabolism—CYP3A4—bone cancer	5.26e-05	0.000719	CbGpPWpGaD
Capecitabine—Immune system disorder—Epirubicin—bone cancer	5.26e-05	0.000504	CcSEcCtD
Capecitabine—Mediastinal disorder—Epirubicin—bone cancer	5.25e-05	0.000503	CcSEcCtD
Capecitabine—Back pain—Methotrexate—bone cancer	5.24e-05	0.000502	CcSEcCtD
Capecitabine—TYMS—Cell Cycle—BRCA2—bone cancer	5.23e-05	0.000716	CbGpPWpGaD
Capecitabine—Chills—Epirubicin—bone cancer	5.22e-05	0.000501	CcSEcCtD
Capecitabine—Arrhythmia—Epirubicin—bone cancer	5.2e-05	0.000499	CcSEcCtD
Capecitabine—Visual impairment—Doxorubicin—bone cancer	5.19e-05	0.000498	CcSEcCtD
Capecitabine—Alopecia—Epirubicin—bone cancer	5.14e-05	0.000493	CcSEcCtD
Capecitabine—Vomiting—Cisplatin—bone cancer	5.12e-05	0.000491	CcSEcCtD
Capecitabine—Vision blurred—Methotrexate—bone cancer	5.1e-05	0.00049	CcSEcCtD
Capecitabine—Mental disorder—Epirubicin—bone cancer	5.1e-05	0.000489	CcSEcCtD
Capecitabine—Erythema multiforme—Doxorubicin—bone cancer	5.09e-05	0.000489	CcSEcCtD
Capecitabine—Rash—Cisplatin—bone cancer	5.08e-05	0.000487	CcSEcCtD
Capecitabine—Dermatitis—Cisplatin—bone cancer	5.07e-05	0.000487	CcSEcCtD
Capecitabine—Erythema—Epirubicin—bone cancer	5.07e-05	0.000486	CcSEcCtD
Capecitabine—Malnutrition—Epirubicin—bone cancer	5.07e-05	0.000486	CcSEcCtD
Capecitabine—Eye disorder—Doxorubicin—bone cancer	5.03e-05	0.000483	CcSEcCtD
Capecitabine—Ill-defined disorder—Methotrexate—bone cancer	5.02e-05	0.000482	CcSEcCtD
Capecitabine—Tinnitus—Doxorubicin—bone cancer	5.02e-05	0.000482	CcSEcCtD
Capecitabine—Anaemia—Methotrexate—bone cancer	5e-05	0.00048	CcSEcCtD
Capecitabine—Flushing—Doxorubicin—bone cancer	5e-05	0.00048	CcSEcCtD
Capecitabine—Cardiac disorder—Doxorubicin—bone cancer	5e-05	0.00048	CcSEcCtD
Capecitabine—Flatulence—Epirubicin—bone cancer	4.99e-05	0.000479	CcSEcCtD
Capecitabine—Dysgeusia—Epirubicin—bone cancer	4.96e-05	0.000476	CcSEcCtD
Capecitabine—Back pain—Epirubicin—bone cancer	4.9e-05	0.00047	CcSEcCtD
Capecitabine—Angiopathy—Doxorubicin—bone cancer	4.89e-05	0.000469	CcSEcCtD
Capecitabine—Malaise—Methotrexate—bone cancer	4.88e-05	0.000468	CcSEcCtD
Capecitabine—Muscle spasms—Epirubicin—bone cancer	4.87e-05	0.000467	CcSEcCtD
Capecitabine—Immune system disorder—Doxorubicin—bone cancer	4.86e-05	0.000467	CcSEcCtD
Capecitabine—Vertigo—Methotrexate—bone cancer	4.86e-05	0.000467	CcSEcCtD
Capecitabine—Mediastinal disorder—Doxorubicin—bone cancer	4.85e-05	0.000466	CcSEcCtD
Capecitabine—Leukopenia—Methotrexate—bone cancer	4.85e-05	0.000465	CcSEcCtD
Capecitabine—Chills—Doxorubicin—bone cancer	4.83e-05	0.000464	CcSEcCtD
Capecitabine—Arrhythmia—Doxorubicin—bone cancer	4.81e-05	0.000462	CcSEcCtD
Capecitabine—Nausea—Cisplatin—bone cancer	4.78e-05	0.000459	CcSEcCtD
Capecitabine—Vision blurred—Epirubicin—bone cancer	4.78e-05	0.000458	CcSEcCtD
Capecitabine—Alopecia—Doxorubicin—bone cancer	4.76e-05	0.000457	CcSEcCtD
Capecitabine—Cough—Methotrexate—bone cancer	4.72e-05	0.000453	CcSEcCtD
Capecitabine—Mental disorder—Doxorubicin—bone cancer	4.72e-05	0.000453	CcSEcCtD
Capecitabine—Ill-defined disorder—Epirubicin—bone cancer	4.7e-05	0.000451	CcSEcCtD
Capecitabine—Erythema—Doxorubicin—bone cancer	4.69e-05	0.00045	CcSEcCtD
Capecitabine—Malnutrition—Doxorubicin—bone cancer	4.69e-05	0.00045	CcSEcCtD
Capecitabine—Anaemia—Epirubicin—bone cancer	4.68e-05	0.000449	CcSEcCtD
Capecitabine—Flatulence—Doxorubicin—bone cancer	4.62e-05	0.000443	CcSEcCtD
Capecitabine—Chest pain—Methotrexate—bone cancer	4.61e-05	0.000442	CcSEcCtD
Capecitabine—Myalgia—Methotrexate—bone cancer	4.61e-05	0.000442	CcSEcCtD
Capecitabine—Arthralgia—Methotrexate—bone cancer	4.61e-05	0.000442	CcSEcCtD
Capecitabine—Dysgeusia—Doxorubicin—bone cancer	4.59e-05	0.00044	CcSEcCtD
Capecitabine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	4.58e-05	0.000439	CcSEcCtD
Capecitabine—Malaise—Epirubicin—bone cancer	4.57e-05	0.000438	CcSEcCtD
Capecitabine—Discomfort—Methotrexate—bone cancer	4.55e-05	0.000437	CcSEcCtD
Capecitabine—Vertigo—Epirubicin—bone cancer	4.55e-05	0.000437	CcSEcCtD
Capecitabine—Syncope—Epirubicin—bone cancer	4.54e-05	0.000436	CcSEcCtD
Capecitabine—TYMS—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	4.54e-05	0.000621	CbGpPWpGaD
Capecitabine—Leukopenia—Epirubicin—bone cancer	4.54e-05	0.000435	CcSEcCtD
Capecitabine—Back pain—Doxorubicin—bone cancer	4.54e-05	0.000435	CcSEcCtD
Capecitabine—CYP2C9—Biological oxidations—CYP3A4—bone cancer	4.53e-05	0.00062	CbGpPWpGaD
Capecitabine—Muscle spasms—Doxorubicin—bone cancer	4.51e-05	0.000432	CcSEcCtD
Capecitabine—TYMP—Metabolism—GSTP1—bone cancer	4.5e-05	0.000615	CbGpPWpGaD
Capecitabine—Palpitations—Epirubicin—bone cancer	4.48e-05	0.00043	CcSEcCtD
Capecitabine—CYP2C9—Metapathway biotransformation—CYP3A4—bone cancer	4.47e-05	0.000611	CbGpPWpGaD
Capecitabine—Confusional state—Methotrexate—bone cancer	4.46e-05	0.000427	CcSEcCtD
Capecitabine—Loss of consciousness—Epirubicin—bone cancer	4.45e-05	0.000427	CcSEcCtD
Capecitabine—Cough—Epirubicin—bone cancer	4.42e-05	0.000424	CcSEcCtD
Capecitabine—Vision blurred—Doxorubicin—bone cancer	4.42e-05	0.000424	CcSEcCtD
Capecitabine—Infection—Methotrexate—bone cancer	4.39e-05	0.000421	CcSEcCtD
Capecitabine—Hypertension—Epirubicin—bone cancer	4.37e-05	0.00042	CcSEcCtD
Capecitabine—Ill-defined disorder—Doxorubicin—bone cancer	4.35e-05	0.000417	CcSEcCtD
Capecitabine—TYMS—Cell Cycle, Mitotic—CDK4—bone cancer	4.34e-05	0.000594	CbGpPWpGaD
Capecitabine—Nervous system disorder—Methotrexate—bone cancer	4.33e-05	0.000416	CcSEcCtD
Capecitabine—Anaemia—Doxorubicin—bone cancer	4.33e-05	0.000416	CcSEcCtD
Capecitabine—Thrombocytopenia—Methotrexate—bone cancer	4.33e-05	0.000415	CcSEcCtD
Capecitabine—Chest pain—Epirubicin—bone cancer	4.31e-05	0.000414	CcSEcCtD
Capecitabine—Arthralgia—Epirubicin—bone cancer	4.31e-05	0.000414	CcSEcCtD
Capecitabine—Myalgia—Epirubicin—bone cancer	4.31e-05	0.000414	CcSEcCtD
Capecitabine—Anxiety—Epirubicin—bone cancer	4.3e-05	0.000412	CcSEcCtD
Capecitabine—Skin disorder—Methotrexate—bone cancer	4.29e-05	0.000412	CcSEcCtD
Capecitabine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	4.28e-05	0.000411	CcSEcCtD
Capecitabine—Hyperhidrosis—Methotrexate—bone cancer	4.27e-05	0.00041	CcSEcCtD
Capecitabine—Discomfort—Epirubicin—bone cancer	4.26e-05	0.000409	CcSEcCtD
Capecitabine—Malaise—Doxorubicin—bone cancer	4.23e-05	0.000406	CcSEcCtD
Capecitabine—Dry mouth—Epirubicin—bone cancer	4.22e-05	0.000405	CcSEcCtD
Capecitabine—Vertigo—Doxorubicin—bone cancer	4.21e-05	0.000404	CcSEcCtD
Capecitabine—Anorexia—Methotrexate—bone cancer	4.21e-05	0.000404	CcSEcCtD
Capecitabine—Syncope—Doxorubicin—bone cancer	4.2e-05	0.000403	CcSEcCtD
Capecitabine—Leukopenia—Doxorubicin—bone cancer	4.2e-05	0.000403	CcSEcCtD
Capecitabine—Confusional state—Epirubicin—bone cancer	4.17e-05	0.0004	CcSEcCtD
Capecitabine—Palpitations—Doxorubicin—bone cancer	4.14e-05	0.000398	CcSEcCtD
Capecitabine—Oedema—Epirubicin—bone cancer	4.14e-05	0.000397	CcSEcCtD
Capecitabine—Hypotension—Methotrexate—bone cancer	4.13e-05	0.000396	CcSEcCtD
Capecitabine—Loss of consciousness—Doxorubicin—bone cancer	4.12e-05	0.000395	CcSEcCtD
Capecitabine—Infection—Epirubicin—bone cancer	4.11e-05	0.000394	CcSEcCtD
Capecitabine—Cough—Doxorubicin—bone cancer	4.09e-05	0.000393	CcSEcCtD
Capecitabine—Shock—Epirubicin—bone cancer	4.07e-05	0.00039	CcSEcCtD
Capecitabine—Nervous system disorder—Epirubicin—bone cancer	4.06e-05	0.000389	CcSEcCtD
Capecitabine—Thrombocytopenia—Epirubicin—bone cancer	4.05e-05	0.000388	CcSEcCtD
Capecitabine—Hypertension—Doxorubicin—bone cancer	4.05e-05	0.000388	CcSEcCtD
Capecitabine—Tachycardia—Epirubicin—bone cancer	4.04e-05	0.000387	CcSEcCtD
Capecitabine—Musculoskeletal discomfort—Methotrexate—bone cancer	4.03e-05	0.000386	CcSEcCtD
Capecitabine—Skin disorder—Epirubicin—bone cancer	4.02e-05	0.000385	CcSEcCtD
Capecitabine—Hyperhidrosis—Epirubicin—bone cancer	4e-05	0.000384	CcSEcCtD
Capecitabine—Insomnia—Methotrexate—bone cancer	4e-05	0.000383	CcSEcCtD
Capecitabine—Arthralgia—Doxorubicin—bone cancer	3.99e-05	0.000383	CcSEcCtD
Capecitabine—Myalgia—Doxorubicin—bone cancer	3.99e-05	0.000383	CcSEcCtD
Capecitabine—Chest pain—Doxorubicin—bone cancer	3.99e-05	0.000383	CcSEcCtD
Capecitabine—Anxiety—Doxorubicin—bone cancer	3.98e-05	0.000382	CcSEcCtD
Capecitabine—Paraesthesia—Methotrexate—bone cancer	3.97e-05	0.000381	CcSEcCtD
Capecitabine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	3.96e-05	0.00038	CcSEcCtD
Capecitabine—Discomfort—Doxorubicin—bone cancer	3.94e-05	0.000378	CcSEcCtD
Capecitabine—Anorexia—Epirubicin—bone cancer	3.94e-05	0.000378	CcSEcCtD
Capecitabine—Dyspnoea—Methotrexate—bone cancer	3.94e-05	0.000378	CcSEcCtD
Capecitabine—Dry mouth—Doxorubicin—bone cancer	3.9e-05	0.000375	CcSEcCtD
Capecitabine—Dyspepsia—Methotrexate—bone cancer	3.89e-05	0.000373	CcSEcCtD
Capecitabine—TYMS—Cell Cycle—CDK4—bone cancer	3.88e-05	0.000531	CbGpPWpGaD
Capecitabine—CYP2C9—Biological oxidations—GSTP1—bone cancer	3.88e-05	0.00053	CbGpPWpGaD
Capecitabine—Hypotension—Epirubicin—bone cancer	3.86e-05	0.000371	CcSEcCtD
Capecitabine—Confusional state—Doxorubicin—bone cancer	3.86e-05	0.00037	CcSEcCtD
Capecitabine—Decreased appetite—Methotrexate—bone cancer	3.84e-05	0.000369	CcSEcCtD
Capecitabine—Oedema—Doxorubicin—bone cancer	3.83e-05	0.000367	CcSEcCtD
Capecitabine—CYP2C9—Metapathway biotransformation—GSTP1—bone cancer	3.83e-05	0.000523	CbGpPWpGaD
Capecitabine—TYMS—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	3.82e-05	0.000522	CbGpPWpGaD
Capecitabine—Gastrointestinal disorder—Methotrexate—bone cancer	3.82e-05	0.000366	CcSEcCtD
Capecitabine—Fatigue—Methotrexate—bone cancer	3.81e-05	0.000366	CcSEcCtD
Capecitabine—Infection—Doxorubicin—bone cancer	3.8e-05	0.000365	CcSEcCtD
Capecitabine—Pain—Methotrexate—bone cancer	3.78e-05	0.000363	CcSEcCtD
Capecitabine—TYMS—Cell Cycle, Mitotic—RB1—bone cancer	3.78e-05	0.000516	CbGpPWpGaD
Capecitabine—Musculoskeletal discomfort—Epirubicin—bone cancer	3.77e-05	0.000361	CcSEcCtD
Capecitabine—Shock—Doxorubicin—bone cancer	3.76e-05	0.000361	CcSEcCtD
Capecitabine—Nervous system disorder—Doxorubicin—bone cancer	3.75e-05	0.00036	CcSEcCtD
Capecitabine—Thrombocytopenia—Doxorubicin—bone cancer	3.75e-05	0.000359	CcSEcCtD
Capecitabine—Insomnia—Epirubicin—bone cancer	3.74e-05	0.000359	CcSEcCtD
Capecitabine—Tachycardia—Doxorubicin—bone cancer	3.73e-05	0.000358	CcSEcCtD
Capecitabine—Skin disorder—Doxorubicin—bone cancer	3.72e-05	0.000357	CcSEcCtD
Capecitabine—Paraesthesia—Epirubicin—bone cancer	3.71e-05	0.000356	CcSEcCtD
Capecitabine—Hyperhidrosis—Doxorubicin—bone cancer	3.7e-05	0.000355	CcSEcCtD
Capecitabine—Dyspnoea—Epirubicin—bone cancer	3.69e-05	0.000354	CcSEcCtD
Capecitabine—TYMS—Circadian rythm related genes—TP53—bone cancer	3.66e-05	0.000501	CbGpPWpGaD
Capecitabine—Anorexia—Doxorubicin—bone cancer	3.65e-05	0.00035	CcSEcCtD
Capecitabine—Feeling abnormal—Methotrexate—bone cancer	3.64e-05	0.000349	CcSEcCtD
Capecitabine—Dyspepsia—Epirubicin—bone cancer	3.64e-05	0.000349	CcSEcCtD
Capecitabine—Gastrointestinal pain—Methotrexate—bone cancer	3.61e-05	0.000347	CcSEcCtD
Capecitabine—Decreased appetite—Epirubicin—bone cancer	3.6e-05	0.000345	CcSEcCtD
Capecitabine—Hypotension—Doxorubicin—bone cancer	3.58e-05	0.000343	CcSEcCtD
Capecitabine—Gastrointestinal disorder—Epirubicin—bone cancer	3.57e-05	0.000343	CcSEcCtD
Capecitabine—Fatigue—Epirubicin—bone cancer	3.57e-05	0.000342	CcSEcCtD
Capecitabine—Pain—Epirubicin—bone cancer	3.54e-05	0.000339	CcSEcCtD
Capecitabine—Constipation—Epirubicin—bone cancer	3.54e-05	0.000339	CcSEcCtD
Capecitabine—Urticaria—Methotrexate—bone cancer	3.51e-05	0.000337	CcSEcCtD
Capecitabine—Body temperature increased—Methotrexate—bone cancer	3.49e-05	0.000335	CcSEcCtD
Capecitabine—Abdominal pain—Methotrexate—bone cancer	3.49e-05	0.000335	CcSEcCtD
Capecitabine—Musculoskeletal discomfort—Doxorubicin—bone cancer	3.49e-05	0.000334	CcSEcCtD
Capecitabine—Insomnia—Doxorubicin—bone cancer	3.46e-05	0.000332	CcSEcCtD
Capecitabine—Paraesthesia—Doxorubicin—bone cancer	3.44e-05	0.00033	CcSEcCtD
Capecitabine—TYMS—Metabolism—ENO2—bone cancer	3.42e-05	0.000468	CbGpPWpGaD
Capecitabine—Dyspnoea—Doxorubicin—bone cancer	3.41e-05	0.000327	CcSEcCtD
Capecitabine—Feeling abnormal—Epirubicin—bone cancer	3.41e-05	0.000327	CcSEcCtD
Capecitabine—Gastrointestinal pain—Epirubicin—bone cancer	3.38e-05	0.000324	CcSEcCtD
Capecitabine—TYMS—Cell Cycle—RB1—bone cancer	3.38e-05	0.000461	CbGpPWpGaD
Capecitabine—Dyspepsia—Doxorubicin—bone cancer	3.37e-05	0.000323	CcSEcCtD
Capecitabine—Decreased appetite—Doxorubicin—bone cancer	3.33e-05	0.000319	CcSEcCtD
Capecitabine—Gastrointestinal disorder—Doxorubicin—bone cancer	3.3e-05	0.000317	CcSEcCtD
Capecitabine—Fatigue—Doxorubicin—bone cancer	3.3e-05	0.000317	CcSEcCtD
Capecitabine—Urticaria—Epirubicin—bone cancer	3.29e-05	0.000315	CcSEcCtD
Capecitabine—Pain—Doxorubicin—bone cancer	3.27e-05	0.000314	CcSEcCtD
Capecitabine—Constipation—Doxorubicin—bone cancer	3.27e-05	0.000314	CcSEcCtD
Capecitabine—DPYD—Metabolism—PTGS2—bone cancer	3.27e-05	0.000447	CbGpPWpGaD
Capecitabine—Body temperature increased—Epirubicin—bone cancer	3.27e-05	0.000314	CcSEcCtD
Capecitabine—Abdominal pain—Epirubicin—bone cancer	3.27e-05	0.000314	CcSEcCtD
Capecitabine—Hypersensitivity—Methotrexate—bone cancer	3.26e-05	0.000312	CcSEcCtD
Capecitabine—TYMS—Metabolism—DHFR—bone cancer	3.18e-05	0.000434	CbGpPWpGaD
Capecitabine—Asthenia—Methotrexate—bone cancer	3.17e-05	0.000304	CcSEcCtD
Capecitabine—Feeling abnormal—Doxorubicin—bone cancer	3.15e-05	0.000303	CcSEcCtD
Capecitabine—Gastrointestinal pain—Doxorubicin—bone cancer	3.13e-05	0.0003	CcSEcCtD
Capecitabine—Pruritus—Methotrexate—bone cancer	3.13e-05	0.0003	CcSEcCtD
Capecitabine—Hypersensitivity—Epirubicin—bone cancer	3.05e-05	0.000292	CcSEcCtD
Capecitabine—Urticaria—Doxorubicin—bone cancer	3.04e-05	0.000292	CcSEcCtD
Capecitabine—Abdominal pain—Doxorubicin—bone cancer	3.02e-05	0.00029	CcSEcCtD
Capecitabine—Body temperature increased—Doxorubicin—bone cancer	3.02e-05	0.00029	CcSEcCtD
Capecitabine—Diarrhoea—Methotrexate—bone cancer	3.02e-05	0.00029	CcSEcCtD
Capecitabine—TYMS—Metabolism—GNA11—bone cancer	2.97e-05	0.000406	CbGpPWpGaD
Capecitabine—Asthenia—Epirubicin—bone cancer	2.97e-05	0.000285	CcSEcCtD
Capecitabine—Pruritus—Epirubicin—bone cancer	2.93e-05	0.000281	CcSEcCtD
Capecitabine—Dizziness—Methotrexate—bone cancer	2.92e-05	0.00028	CcSEcCtD
Capecitabine—CDA—Metabolism—PTGS2—bone cancer	2.92e-05	0.000398	CbGpPWpGaD
Capecitabine—TYMS—Cell Cycle—MDM2—bone cancer	2.88e-05	0.000393	CbGpPWpGaD
Capecitabine—Diarrhoea—Epirubicin—bone cancer	2.83e-05	0.000271	CcSEcCtD
Capecitabine—Hypersensitivity—Doxorubicin—bone cancer	2.82e-05	0.00027	CcSEcCtD
Capecitabine—Vomiting—Methotrexate—bone cancer	2.81e-05	0.00027	CcSEcCtD
Capecitabine—Rash—Methotrexate—bone cancer	2.79e-05	0.000267	CcSEcCtD
Capecitabine—Dermatitis—Methotrexate—bone cancer	2.78e-05	0.000267	CcSEcCtD
Capecitabine—Headache—Methotrexate—bone cancer	2.77e-05	0.000266	CcSEcCtD
Capecitabine—Asthenia—Doxorubicin—bone cancer	2.75e-05	0.000263	CcSEcCtD
Capecitabine—Dizziness—Epirubicin—bone cancer	2.73e-05	0.000262	CcSEcCtD
Capecitabine—CYP2C9—Metabolism—NDUFA12—bone cancer	2.72e-05	0.000372	CbGpPWpGaD
Capecitabine—Pruritus—Doxorubicin—bone cancer	2.71e-05	0.00026	CcSEcCtD
Capecitabine—TYMS—Metabolism—CYP3A4—bone cancer	2.69e-05	0.000368	CbGpPWpGaD
Capecitabine—Vomiting—Epirubicin—bone cancer	2.63e-05	0.000252	CcSEcCtD
Capecitabine—Nausea—Methotrexate—bone cancer	2.62e-05	0.000252	CcSEcCtD
Capecitabine—Diarrhoea—Doxorubicin—bone cancer	2.62e-05	0.000251	CcSEcCtD
Capecitabine—Rash—Epirubicin—bone cancer	2.61e-05	0.00025	CcSEcCtD
Capecitabine—Dermatitis—Epirubicin—bone cancer	2.61e-05	0.00025	CcSEcCtD
Capecitabine—Headache—Epirubicin—bone cancer	2.59e-05	0.000249	CcSEcCtD
Capecitabine—Dizziness—Doxorubicin—bone cancer	2.53e-05	0.000243	CcSEcCtD
Capecitabine—Nausea—Epirubicin—bone cancer	2.46e-05	0.000236	CcSEcCtD
Capecitabine—Vomiting—Doxorubicin—bone cancer	2.43e-05	0.000233	CcSEcCtD
Capecitabine—Rash—Doxorubicin—bone cancer	2.41e-05	0.000231	CcSEcCtD
Capecitabine—Dermatitis—Doxorubicin—bone cancer	2.41e-05	0.000231	CcSEcCtD
Capecitabine—Headache—Doxorubicin—bone cancer	2.4e-05	0.00023	CcSEcCtD
Capecitabine—TYMP—Metabolism—PTGS2—bone cancer	2.33e-05	0.000319	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—GSTP1—bone cancer	2.3e-05	0.000315	CbGpPWpGaD
Capecitabine—Nausea—Doxorubicin—bone cancer	2.27e-05	0.000218	CcSEcCtD
Capecitabine—CYP2C9—Metabolism—NT5C3A—bone cancer	2.25e-05	0.000308	CbGpPWpGaD
Capecitabine—TYMS—Cell Cycle—TP53—bone cancer	1.65e-05	0.000226	CbGpPWpGaD
Capecitabine—TYMS—Metabolism—PTGS2—bone cancer	1.19e-05	0.000163	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—ENO2—bone cancer	9.87e-06	0.000135	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—DHFR—bone cancer	9.15e-06	0.000125	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—GNA11—bone cancer	8.55e-06	0.000117	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—CYP3A4—bone cancer	7.76e-06	0.000106	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	7.72e-06	0.000105	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—GSTP1—bone cancer	6.63e-06	9.07e-05	CbGpPWpGaD
Capecitabine—CYP2C9—Metabolism—PTGS2—bone cancer	3.44e-06	4.7e-05	CbGpPWpGaD
